Objectives This study aimed to investigate the association between thiazide use and the risk of hip fracture after stroke.
Setting A population-based, propensity-matched cohort study was conducted on the basis of Taiwan’s National Health Insurance Research Database.
Participants Patients with newly diagnosed ischaemic stroke between 2000 and 2011 were included. After propensity score matching, 7470 patients were included, of whom 3735 received thiazides and 3735 did not.
Outcome measures HRs for developing hip fractures within 2 years after stroke were calculated using Cox proportional hazards regression model with adjustments for sociodemographic and coexisting medical conditions.
Results Overall, patients using thiazides after stroke had a lower risk of hip fracture than those not using thiazides (8.5 vs 13.9 per 1000 person-years, adjusted HR=0.64, 95% CI 0.46 to 0.89, p=0.007). Further sensitivity analysis based on the duration of thiazide use revealed that the risk of hip fracture tended to decrease as the duration of exposure of thiazides increased. However, the effect was significant only in patients with long-term use of thiazides (using thiazides for >365 days within 2 years after stroke), with a 59% reduction in the risk of hip fracture when compared with patients not using thiazide (adjusted HR=0.41, 95% CI 0.22 to 0.79, p=0.008).
Conclusions The long-term use of thiazides is associated with a decreased risk of hip fracture after stroke.
- Hip Fracture
- Bone Mineral Density
- Cohort Study
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Contributors Study conception and design: S-ML, S-HY and H-KH; acquisition of data: S-HY and H-KH; analysis and interpretation of data: S-ML, S-HY, H-YC, C-CL and H-KH; drafting of manuscript: S-ML and H-KH; critical revision: S-ML, S-HY, H-YC, C-CL and H-KH.
Competing interests None declared.
Ethics approval The study protocol was approved by the Institutional Review Board of Tzu Chi Medical Center (REC No: IRB104-131C).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All relevant data are within the paper. No additional data are available.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.